- Pharmaceutical Products
- Products By Brand Name
- Products By Dosage Form
- Products By Generic Name
- Products By Therapeutic Class
Find a product
Find Generic
Tompag
Eltrombopag Olamine
Description:
Tompag® tablet contains Eltrombopag Olamine as active ingredient. It is an antithrombin agent.
Tompag® tablet contains Eltrombopag Olamine as active ingredient. It is an antithrombin agent.
Indications:
Treatment of Thrombocytopenia in Patients with Chronic ITP: Tompag® is indicated for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Tompag® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Treatment of Thrombocytopenia in Patients with Hepatitis C Infection: Tompag® should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. Treatment of Severe Aplastic Anemia: Tompag® is indicated for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy
Treatment of Thrombocytopenia in Patients with Chronic ITP: Tompag® is indicated for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Tompag® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Treatment of Thrombocytopenia in Patients with Hepatitis C Infection: Tompag® should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. Treatment of Severe Aplastic Anemia: Tompag® is indicated for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy
Mode of Action:
Eltrombopag Olamine is a thrombopoietin (TPO) receptor agonist. Eltrombopag interacts with the transmembrane domain of the TPO receptor (also known as cMpl) leading to increased platelet production.
Eltrombopag Olamine is a thrombopoietin (TPO) receptor agonist. Eltrombopag interacts with the transmembrane domain of the TPO receptor (also known as cMpl) leading to increased platelet production.
Other Brands From Same Therapeutic Class
